Press Releases




Return to Press Releases

Mahwah, NJ, May 4, 2004 – DOBI Medical International, Inc. (“DBMI.OB”) announced today its financial results for the first fiscal quarter of 2004, ended MARCH 31. The net loss for the first quarter of 2004 was approximately $1.3 million, or $.03 per share, compared with a net loss of approximately $1.1 million, or $.06 per share in the comparable prior year quarter.
Phillip C. Thomas, DOBI Medical International’s Chief Executive Officer commented, “The management team is on plan with respect to its operational objectives, which includes starting production of the ComfortScan™ system for international deliveries by September 2004 and the commencement of the clinical trial for module 5 of the company’s PMA submission to the FDA by that same month. I am also pleased that our management team has met its operational objectives within our budget through the first quarter of 2004.”
During the first quarter of 2004 the Company also bolstered its executive ranks by electing Robert B. Machinist, one of the co-founders of Patricof and Company Capital Corp as its non-executive Board Chairman. In addition, DOBI Medical named Denis A. O’Connor, a 20 year veteran of the medical device industry, to head its sales and marketing; Dr. Angelo Secci, an expert in angiogenesis research as its VP, Clinical Research; Robert Sohval, PhD, who has 25 years experience in the diagnostic imaging industry as R&D head; and Sal Lucia, seasoned by two decades of senior experience in the medical imaging and capital equipment industries, Director, Operations. “DOBI Medical now has the full complement of experienced senior management necessary to successfully implement our business plan and carry out our expansion plans during 2004 and beyond,” noted Mr. Thomas.

About DOBI Medical International, Inc.
DOBI Medical International is an advanced development stage medical imaging company working to create a new means for the improved diagnosis of cancer through the detection of abnormal vascularization ("angiogenesis") associated with tumors. DOBI Medical International’s first application of the technology is the ComfortScan™ system, a non-invasive, non-ionizing, and pain-free optical imaging system designed to assist physicians in the detection and management of breast cancer. The ComfortScan™ system is intended to achieve this by providing new, physiology-based imagery of abnormal vascularization in the breast that are not readily available today.

DOBI Medical International, Inc. and Subsidiary
(A Development Stage Company)
Condensed Consolidated Statements of Operations

Three months ended
March 31,


Research and development expenses
General and administrative expenses
Clinical program expenses
Sales and marketing expenses
Interest expense
Interest income
Net loss

Basic and diluted loss per common share

Weighted average common shares, basic and diluted


$ 503,639
$ (1,313,333)

$ 0.03



$ 328,053

$ 0.06


The unaudited financial information included in this document is intended only as summary provided for your convenience, and should be read in conjunction with the complete consolidated financial statements of the Company (including the Notes thereto, which set forth important information) contained in its Reports on Form 10-K and 10-Q filed by the Company with the U.S. Securities and Exchange Commission (SEC). Such reports are available on the public EDGAR electronic filing system maintained by the SEC.

Cautionary Statement Regarding Forward Looking Statements
This release may contain information that includes or is based upon certain “forward-looking statements” within the meaning of the Securities Litigation Reform Act 1995, relating to the business of DOBI Medical. These forward looking statements represent management’s current judgment and assumptions and can be identified by the fact that they do not relate strictly to historical or current facts. Forward looking statements are frequently accompanied by the use of such words as “anticipate”, “plans”, “believes”, “expects”, “project”, “intends”, or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties, including uncertainties relating to our ability to secure additional financing; success of product development efforts; our ability to timely meet government and industry regulations and standards; delays in the manufacturing process caused by our inabilities or the inability of our subcontractors to timely meet our specifications; our ability to establish international and domestic distribution networks, our ability to timely export our products to international markets; acceptance of the ComfortScan system as an adjunct to mammography by physicians, imaging clinics, and patients; our ability to obtain third party payer reimbursement; and our ability to compete on price and quality. Any one of these or other risks and uncertainties may cause actual results to be materially different from those described herein or elsewhere by us. Certain of these risks and uncertainties are or will be described in greater detail in our filings from time to time with the Securities and Exchange Commission, which we strongly urge you to read. Subsequent written and oral forward looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the cautionary statements and risk factors set forth above and elsewhere and in our reports filed with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward looking statements.

Return to Press Releases

For further information:
Please contact: Phillip C. Thomas, Chief Executive Officer

DOBI Medical International
1200 MacArthur Blvd.
Mahwah, New Jersey 07430
Voice: (201) 760 6464
Fax: (201) 760 8860


calendario | newsletter | relacoes | atribuicoes | acidentesincidentes | legisot | reflegisd | apresentacao | missao | contactos
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 1 | 2 | 3 | 4 | 5